Vagus nerve surgery encompasses both procedures that deliberately cut or modify the vagus nerve (vagotomy) and procedures that implant devices to stimulate it (VNS implantation). These are fundamentally different operations with opposite goals — one reduces vagal function, the other enhances it. Understanding the benefits, risks, and current status of each is essential for anyone considering surgical intervention involving the vagus nerve.
Vagotomy: Cutting the Vagus Nerve
Vagotomy — surgical division of the vagus nerve — was one of the most common abdominal operations of the 20th century. Performed to treat peptic ulcer disease, vagotomy worked by eliminating the vagal stimulation of gastric acid secretion from parietal cells, reducing acid output by approximately 50-70 percent. Three types were performed: truncal vagotomy (cutting both vagal trunks at the oesophageal hiatus — maximum acid reduction but severe side effects), selective vagotomy (cutting the gastric branches while preserving the hepatic and coeliac branches), and highly selective vagotomy (parietal cell vagotomy — cutting only the branches to the acid-producing fundus and body of the stomach while preserving the branches to the antrum and pylorus).
Vagotomy has been largely abandoned since the introduction of proton pump inhibitors in the late 1980s. PPIs achieve comparable acid suppression without surgery, without permanent vagal damage, and with a reversible mechanism. However, understanding vagotomy remains clinically relevant because many patients who underwent vagotomy in the 1970s-1990s continue to live with its consequences (gastroparesis, dumping syndrome, diarrhoea), and because surgical vagal injury remains an unintended complication of other operations.
Risks and consequences of vagotomy. Truncal vagotomy produced gastroparesis in 10-20 percent of patients (complete loss of vagal gastric motility), dumping syndrome in 10-25 percent (rapid gastric emptying of hyperosmolar contents into the duodenum, causing nausea, diarrhoea, vasomotor symptoms), post-vagotomy diarrhoea in 5-10 percent, and nutritional consequences (impaired B12 absorption, reduced iron absorption due to reduced gastric acid). Highly selective vagotomy had far fewer side effects (less than 5 percent gastroparesis rate) because it preserved the vagal branches controlling gastric motility.
VNS Implantation: Stimulating the Vagus Nerve
VNS implantation is the surgical placement of a stimulation device that delivers controlled electrical pulses to the left vagus nerve. The standard system (LivaNova) consists of a pulse generator implanted subcutaneously in the left chest wall and a bipolar lead electrode wrapped around the left cervical vagus nerve.
FDA-approved indications. VNS is FDA-approved for drug-resistant epilepsy (since 1997 — the longest-established indication) and treatment-resistant depression (since 2005). Drug-resistant epilepsy is defined as inadequate seizure control despite adequate trials of at least two antiepileptic drugs. Treatment-resistant depression is defined as failure to respond to at least four adequate trials of antidepressant medications.
Surgical procedure. VNS implantation is performed under general anaesthesia and takes approximately 1-2 hours. Two incisions are made: one in the left neck to expose the vagus nerve in the carotid sheath, and one in the left chest wall to create a subcutaneous pocket for the pulse generator. The helical electrodes are carefully wrapped around the vagus nerve, and the lead is tunnelled subcutaneously from the neck to the chest pocket. The left vagus is used because the right vagus has more cardiac efferent fibres, and stimulation carries a higher risk of cardiac arrhythmia.
The device is typically turned on 2-4 weeks after surgery (to allow post-operative healing) and parameters are gradually increased over subsequent visits. The standard stimulation cycle is 30 seconds on, 5 minutes off, delivered continuously. Parameters (current intensity, pulse width, frequency, duty cycle) are adjusted by the neurologist using an external programmer.
Benefits. For epilepsy, approximately 40-50 percent of patients achieve a 50 percent or greater reduction in seizure frequency at 2-3 years of treatment. Efficacy tends to improve over time (the responder rate increases between years 1 and 3). A minority of patients (5-8 percent) achieve seizure freedom. For depression, response rates in clinical trials have been approximately 30-40 percent at 1 year, with some patients showing continued improvement over 2 years. VNS for depression has been more controversial than for epilepsy, partly because the pivotal trial did not show statistical significance at its primary endpoint, and long-term open-label data — while encouraging — is less rigorous than controlled trial data.
Risks and side effects. Surgical complications include infection (3-6 percent), vocal cord paralysis (approximately 1 percent — from manipulation of the vagus nerve during electrode placement), lead fracture or displacement (requiring revision surgery), and haematoma. Stimulation-related side effects include hoarseness during stimulation (50-60 percent — the most common side effect, resolves when stimulation cycles off), throat pain or tingling (10-25 percent), cough during stimulation (10-20 percent), and dyspnoea during stimulation (5-15 percent). These stimulation side effects generally diminish with time and can be managed by adjusting stimulation parameters.
Device-related considerations include battery replacement every 5-10 years (requiring a minor procedure to replace the pulse generator), MRI restrictions (older VNS models are MRI-incompatible; newer models allow limited MRI under specific conditions), and the permanence of the implant (the lead electrodes become encased in scar tissue and are generally not removed even if the device is turned off — removal carries a risk of vagal injury).
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Emerging Surgical Approaches
Closed-loop VNS. Newer VNS devices incorporate responsive (closed-loop) features that detect cardiac or EEG changes associated with seizure onset and deliver additional stimulation bursts in response. This approach may improve efficacy by providing targeted stimulation when it is most needed. The SenTiva and newer models from LivaNova include cardiac-based seizure detection.
Non-invasive alternatives. The development of non-invasive VNS devices (gammaCore for headache, and consumer taVNS devices) has reduced the need for surgical implantation in conditions where non-invasive stimulation provides adequate benefit. For epilepsy and treatment-resistant depression specifically, however, the stimulation parameters achievable non-invasively are generally lower than those delivered by implanted devices, and the clinical evidence is less robust. For a comprehensive review of the device landscape, see our article on the best vagus nerve stimulation devices.
Whether considering vagal surgery or wanting to avoid it, understanding the options is essential. My Vagus Nerve & Me covers the full spectrum of vagal interventions — from self-directed techniques to clinical devices to surgical options. Get My Vagus Nerve & Me eBook and make an informed decision about your vagal health.
